16th Jun 2014 10:52
LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-related macular degeneration, diabetic retinopathy and wound healing.
When a compound is optically pure it contains only one enantiomer, a pair of molecules that are mirror images of one another.
The patent was developed in collaboration with the Centre National de la Recherche Scientifique. It has been granted a similar patent in the EU, Japan and Australia.
"We are pleased to see our research efforts rewarded and to add to our extensive patent portfolio. It is important for us to keep ahead of innovation in the industry and this broadens the company's pipeline and takes us in new exciting areas of unmet medical need," said Chief Scientific Officer and ImmuPharma President Robert Zimmer in a statement.
Shares in ImmuPharma were trading up 1.9% at 47.40 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma